Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics
dc.contributor.author | Pescovitz, M. D. | en_US |
dc.contributor.author | Conti, D. | en_US |
dc.contributor.author | Dunn, J. | en_US |
dc.contributor.author | Gonwa, T. | en_US |
dc.contributor.author | Halloran, Phil | en_US |
dc.contributor.author | Sollinger, H. W. | en_US |
dc.contributor.author | Tomlanovich, S. | en_US |
dc.contributor.author | Weinstein, S. | en_US |
dc.contributor.author | Inokuchi, S. | en_US |
dc.contributor.author | Kiberd, B. | en_US |
dc.contributor.author | Kittur, D. | en_US |
dc.contributor.author | Merion, Robert M. | en_US |
dc.contributor.author | Norman, D. | en_US |
dc.contributor.author | Shoker, A. | en_US |
dc.contributor.author | Wilburn, R. | en_US |
dc.contributor.author | Nicholls, Aj | en_US |
dc.contributor.author | Arterburn, S. | en_US |
dc.contributor.author | Dumont, E. | en_US |
dc.date.accessioned | 2010-06-01T19:06:14Z | |
dc.date.available | 2010-06-01T19:06:14Z | |
dc.date.issued | 2000-06 | en_US |
dc.identifier.citation | Pescovitz, Md; Conti, D; Dunn, J; Gonwa, T; Halloran, P; Sollinger, H; Tomlanovich, S; Weinstein, S; Inokuchi, S; Kiberd, B; Kittur, D; Merion, Rm; Norman, D; Shoker, A; Wilburn, R; Nicholls, Aj; Arterburn, S; Dumont 1 , E (2000). "Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics." Clinical Transplantation 14(3): 179-188. <http://hdl.handle.net/2027.42/72291> | en_US |
dc.identifier.issn | 0902-0063 | en_US |
dc.identifier.issn | 1399-0012 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72291 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10831074&dopt=citation | en_US |
dc.format.extent | 329630 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Munksgaard International Publishers | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | Munksgaard 2000 | en_US |
dc.subject.other | Intravenous (I.V.) | en_US |
dc.subject.other | Kidney Transplantation | en_US |
dc.subject.other | Mycophenolate Mofetil | en_US |
dc.subject.other | Pharmacokinetics | en_US |
dc.subject.other | Safety | en_US |
dc.title | Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, MI, USA; | en_US |
dc.contributor.affiliationother | Indiana University Hospital, Indianapolis, IN; | en_US |
dc.contributor.affiliationother | Albany Medical College, New York, NY, USA; | en_US |
dc.contributor.affiliationother | University of California at San Diego Medical Center, CA, USA; | en_US |
dc.contributor.affiliationother | Baylor University Medical Center, Dallas, TX, USA; | en_US |
dc.contributor.affiliationother | University of Alberta, Edmonton, Canada; | en_US |
dc.contributor.affiliationother | University of Wisconsin, Madison, WI, USA; | en_US |
dc.contributor.affiliationother | University of California, San Francisco, CA, USA; | en_US |
dc.contributor.affiliationother | Tampa General Hospital, FL, USA; | en_US |
dc.contributor.affiliationother | California Pacific Medical Center, San Francisco, CA, USA; | en_US |
dc.contributor.affiliationother | Victoria Transplant Program, Halifax, Nova Scotia, Canada; | en_US |
dc.contributor.affiliationother | Johns Hopkins Hospital, Baltimore, MD, USA; | en_US |
dc.contributor.affiliationother | Oregon Health Sciences University, Portland, OR, USA; | en_US |
dc.contributor.affiliationother | Royal University Hospital, Saskatoon, Saskatchewan, Canada; | en_US |
dc.contributor.affiliationother | Virginia Mason Medical Center, Seattle, WA, USA; | en_US |
dc.contributor.affiliationother | Roche Pharmaceuticals, Palo Alto, CA, USA | en_US |
dc.identifier.pmid | 10831074 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72291/1/j.1399-0012.2000.140301.x.pdf | |
dc.identifier.doi | 10.1034/j.1399-0012.2000.140301.x | en_US |
dc.identifier.source | Clinical Transplantation | en_US |
dc.identifier.citedreference | 1 Sollinger HW, for The US Renal Transplant Mycophenolate Mofetil Study Group Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225. | en_US |
dc.identifier.citedreference | 2 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61 ( 7 ): 1029. | en_US |
dc.identifier.citedreference | Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998: 66: 507. | en_US |
dc.identifier.citedreference | 4 Mathew TH, for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998: 65: 1450. | en_US |
dc.identifier.citedreference | Lee WA, Gu L, Miksztal AR et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990: 7 ( 2 ): 161. | en_US |
dc.identifier.citedreference | Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transpl Proc 1991: 23 ( 2 ): 15. | en_US |
dc.identifier.citedreference | Kimball J, Pescovitz MD, Book BK et al. Mycophenolate mofetil reduces human IgG anti-ATGAM antibody formation. Transplantation 1995: 60: 1379. | en_US |
dc.identifier.citedreference | Smith KGC, Isbel NM, Catton MG et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transpl 1998: 13: 160. | en_US |
dc.identifier.citedreference | Bullingham R, Monroe S, Nicholls A et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in health subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996: 36 ( 4 ): 315. | en_US |
dc.identifier.citedreference | Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharm 1998: 34 ( 6 ): 429. | en_US |
dc.identifier.citedreference | Nicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998: 31 ( 5 ): 329. | en_US |
dc.identifier.citedreference | Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration–clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem 1998: 44 ( 2 ): 381. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.